Tim Van Hauwermeiren | CEO |
Karl Gubitz | CFO |
Keith Woods | COO |
Akash Tewari | Jefferies |
James Gordon | JP Morgan |
Danielle Brill | Raymond James |
Yatin Suneja | Guggenheim |
Joon Lee | Truist |
Tazeen Ahmad | Bank of America |
Rosie Turner | Barclays |
Jason Butler | JMP Securities |
Joel Beatty | Robert W. Baird |
Yanan Zhu | Wells Fargo |
Douglas Tsao | H. C. Wainwright |
Charles Pitman | Redburn |
Emmanuel Papadakis | Deutsche Bank |
[Call Starts Abruptly] This might explain why patients consistently switch between treatments.
Finally, there is a considerable market opportunity with approximately 16,000 to 17,000 addressable patients in the U.S. alone.
We are continuing to enroll patients in the ADVANCE SUBCU, ADHERE, and ADDRESS trials for ITP, CIDP, and Vulgaris, respectively, which are shown on Slide 7, 8, and 9.
As we approach enrollment completion, we will be able to provide more granular standing for these results.